Abstract
Anxiety is characterized by excessive fear that persists and interferes with a person's daily activities. In this study, a new class of 16 derivatives of 2-(Substituted Aryl)-piperazine-3-phenyl-4(3H)-quinazolinones were synthesized, and all of the derivatives were tested for their ability to reduce anxiety using the holeboard test and the elevated plus maize test, administered intraperitoneally to mice at doses of 10 mg/kg body weight. Test compounds 3-phenyl-2-(4-(3-methylphenyl) piperazin-1-yl)quinazolin-4(3H)-one (SD-05), 2-(4-(2-fluorophenyl) piperazin-1-yl)-3-phenylquinazolin-4(3H)-one (SD-06), 3-phenyl-2-(4- (4-methoxyphenyl) piperazin-1-yl)-quinazolin-4(3H)-one (SD-10) showed an increased number of head pocking (56 ± 3.5 to 70 ± 1) as compare to control group number of head pocking (27 ± 3) and increased duration of pocking (50 ± 12 ns) as compare to control group duration of pocking (25 ± 2) in hole board test and increased time spent in open arm (35.5 ± 1.5) and a number of entries in open arm (12.5 ± 0.50) as compare to control group. Test compounds SD-05, SD-06, SD-10 showed significant antianxiety activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmaceutical Sciences and Drug Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
